Amarin (AMRN) Shares Pare Loss as Traders Sell First, Ask Questions Later
Tweet
Share
E-mail
Get Alerts AMRN Hot Sheet
Up)Join SI Premium – FREE
Downside in shares of Amarin (Nasdaq: AMRN) being attributed to an update on the USPTO website showing final rejection on March 14th for the company's 13/272,520 patent.
Amarin shares rose nearly 30 percent last week amid continued positive updates on the company's 12/052,598 patent.
The stock initially dipped more than 6 percent as the '520 update began hitting wires, however shares have now bounced off session lows and are down just 0.5 percent to $10.47.
Amarin shares rose nearly 30 percent last week amid continued positive updates on the company's 12/052,598 patent.
The stock initially dipped more than 6 percent as the '520 update began hitting wires, however shares have now bounced off session lows and are down just 0.5 percent to $10.47.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Elevance Health (ELV) hikes 2024 earnings outlook, shares climb
- Tesla (TSLA) continues to slide, breaks under $150
- Verastem Oncology (VSTM) Appoints John Hayslip to Chief Medical Officer
Create E-mail Alert Related Categories
Corporate News, Momentum MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
